Frazier Life Sciences Management’s Vaxcyte PCVX Stock Holding History

Frazier Life Sciences Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-474,405	Closed	-$17.1M	–	49
2025 Q3	$17.1M	Hold	474,405	–	–	0.51%	32
2025 Q2	$15.4M	Sell	474,405 -65,000	-12%	-$2.13M	0.62%	33
2025 Q1	$20.4M	Hold	539,405	–	–	0.93%	22
2024 Q4	$44.2M	Sell	539,405 -340,000	-39%	-$33.8M	1.83%	13
2024 Q3	$100M	Sell	879,405 -160,000	-15%	-$14.4M	4.03%	7
2024 Q2	$78.5M	Sell	1,039,405 -100,000	-9%	-$6.81M	3.67%	10
2024 Q1	$77.8M	Sell	1,139,405 -25,000	-2%	-$1.73M	3.28%	10
2023 Q4	$73.1M	Hold	1,164,405	–	–	3.91%	8
2023 Q3	$59.4M	Hold	1,164,405	–	–	3.94%	7
2023 Q2	$58.2M	Sell	1,164,405 -233,000	-17%	-$11M	3.47%	10
2023 Q1	$52.4M	Hold	1,397,405	–	–	3.79%	10
2022 Q4	$67M	Sell	1,397,405 -150,000	-10%	-$5.89M	4.17%	11
2022 Q3	$37.1M	Sell	1,547,405 -240,000	-13%	-$6.08M	2.86%	10
2022 Q2	$38.9M	Sell	1,787,405 -522,149	-23%	-$12.1M	3.67%	10
2022 Q1	$55.8M	Buy	+2,309,554	New	+$50.5M	4.75%	7

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Frazier Life Sciences Management's PCVX Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 474,405 shares — an estimated $17.1M sold.

Frazier Life Sciences Management first reported a position in PCVX in Q1 2022 and held it in 15 quarters. The position peaked at $100M in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Frazier Life Sciences Management reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 474,405 Vaxcyte shares in Q4 2025, an estimated $17.1M.
Frazier Life Sciences Management first reported a position in Vaxcyte in Q1 2022 and held it in 15 quarters.
Frazier Life Sciences Management's Vaxcyte position peaked at $100M in Q3 2024.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.